Patent US4358394A successfully refreshed from Google Patents.
US4358394A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Process for preparing whole blood reference controls having long term stability
Assignee: Coulter Electronics Inc
•
Filing: 1981-08-12
•
Granted: 1982-11-09
•
Expires: 2001-08-12
Abstract
Abstract A process for preparing whole blood reference controls having long term stability up to six months for devices using electronic means for whole blood determinations including platelet count and mean cell volume and red blood distribution width. The preconditioning diluent for the red blood cells consists essentially of an aqueous solution of lactose, sodium azide, and a non-ionic surfactant and is pH buffered and osmolality adjusted. The media of the whole blood control includes lactose, fungicides and antibiotics, and supplementary agents including purine nucleosides. It also includes additional components which alter red blood cell membranes including bile salts and cholic acid derivatives, phenothiazine compounds and the salts thereof having antihistamine properties, and 4-aminobenzoic acid ester derivatives and their salts having local anesthetic properties. In the process, the red blood cells are separated from the whole blood and preconditioned by the diluent to attain desired size distribution width and volume. The preconditioned red blood cells then are mixed in the media in suitable number for yielding the desired cell count for the whole blood reference control.
Inventors
- 👤 Harold R. Crews
- 👤 David L. Chastain, Jr.
- 👤 Stephen L. Ledis
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-02 07:27
CPC Classifications
G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/96; G01N2496/00; G01N2496/05; Y; Y10; Y10T; Y10T436/00; Y10T436/10; Y10T436/101666; Y10T436/105831
Claims Analysis
Total Claims: 11
Claim 1
Independent Claim
217 words
A process for preparing a whole blood reference control having long term stability for devices using electronic means for whole blood determinations, which comprises the steps of: a. removing the plasma from whole blood to obtain packed red blood cells; b. diluting said packed red blood cells in a preconditioning diluent which includes lactose and a non-ionic surfactant for enhancing the separation of step (d); c. allowing the dilution of step (b) to stand for a preconditioning period of time and temperature which yields a preconditioning to the red blood cells equivalent to the combination of approximately two days at 22° C. to 27° C. for attaining desired red blood cell volume and size distribution width; d. separating the preconditioned red blood cells from the dilution of step (c); and e. adding a sufficient amount of the preconditioned red blood cells of step (d) to a media which is an aqueous solution of lactose, compatible bacteriostatic and fungicidal agents, albumen and at least one ingredient selected from the following groups: (A) Bile salts and cholic acid derivatives; and (B) Phenothiazine compounds having antihistamine properties, said media being osmotically balanced at a preselected and controlled pH, in a total amount sufficient to act as a cell membrane stabilizer, but insufficient to cause lysing of said red blood cells.
Claim 2
Dependent Claim
217 words
A process for preparing a whole blood reference control having long term stability for devices using electronic means for whole blood determinations, which comprises the steps of: a. removing the plasma from whole blood to obtain packed red blood cells; b. diluting said packed red blood cells in a preconditioning diluent which includes lactose and a non-ionic surfactant for enhancing the separation of step (d); c. allowing the dilution of step (b) to stand for a preconditioning period of time and temperature which yields a preconditioning to the red blood cells equivalent to the combination of approximately two days at 22° C. to 27° C. for attaining desired red blood cell volume and size distribution width; d. separating the preconditioned red blood cells from the dilution of step (c); and e. adding a sufficient amount of the preconditioned red blood cells of step (d) to a media which is an aqueous solution of lactose, compatible bacteriostatic and fungicidal agents, albumen and at least one ingredient selected from the following groups: (A) Bile salts and cholic acid derivatives; and (B) Phenothiazine compounds having antihistamine properties, said media being osmotically balanced at a preselected and controlled pH, in a total amount sufficient to act as a cell membrane stabilizer, but insufficient to cause lysing of said red blood cells.
Claim 3
Dependent Claim
23 words
The process of claim 1 wherein the preconditioning diluent consists essentially of an aqueous solution of lactose, sodium azide, and a non-ionic surfactant.
Claim 4
Dependent Claim
34 words
The process of claim 2 wherein said preconditioning diluent is buffered to have a pH within the range of 6.5 to 7.5, and is adjusted to an osmolality within the range of 350-360 mOsm/kg.
Claim 5
Dependent Claim
12 words
The process of claim 1 wherein said non-ionic surfactant comprises Pluronic F68.
Claim 6
Dependent Claim
16 words
The process of claim 1 wherein the red blood cells are obtained from fresh whole blood.
Claim 7
Dependent Claim
16 words
The process of claim 1 wherein the red blood cells are obtained from expired whole blood.
Claim 8
Dependent Claim
15 words
The process of claim 1 wherein the red blood cells are human red blood cells.
Claim 9
Dependent Claim
15 words
The process of claim 1 wherein the red blood cells are animal red blood cells.
Claim 10
Dependent Claim
16 words
The process of claim 1 wherein said whole blood reference control includes human or surrogate platelets.
Claim 11
Dependent Claim
21 words
The process of claim 1 wherein said whole blood determination includes the measurement of the parameter of red cell distribution width.
References Cited (Backward Citations)
US3574137A
Cited
US3956477A
Cited
US3873467A
Cited
US3977995A
Cited
US3962125A
Cited
US4102810A
Cited
US3973913A
Cited
US4289756A
Cited
US4179398A
Cited
US4213876A
Cited
US4264470A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1985-11-08 | 1986-05-10 | 1986-11-09 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1989-11-08 | 1990-05-10 | 1990-11-09 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1993-11-08 | 1994-05-10 | 1994-11-09 | $7700.00 | Window Closed / Lapsed |